Access and/or Protection? Andrey Shastitko MSU, RANEPA.

Slides:



Advertisements
Similar presentations
The GE/Honeywell merger and the issue of bundling.
Advertisements

Cure’s GTX Licensing Opportunity
The Monopoly Problem Breaking up is hard to do. A story. Some theory. Public policy. John D. Rockefeller,
Competition Policy Vertical Restraints.
MICROECONOMICS: Theory & Applications Chapter 11 Monopoly
Course Wrap-up. What is IO? Study of how firms behave in markets Key role of strategic interaction Tools: – Neoclassical comparative static analysis e.g.
Tradeoffs in Competitive Positioning Strategy Dr. Theodore H. K. Clark Associate Professor and Academic Director of MSc in Information Systems Management.
Law and Economics-Charles W. Upton Tests for a Monopoly.
Industrial Organization Economists have developed a branch of economic analysis called Industrial Organization to trace the relationship between the structure.
Introduction to Business Analysis (and Competitive Strategy) Dr. Theodore H. K. Clark Associate Professor and Academic Director of MSc in Information Systems.
Some basic observations
I. A Simple Model. Players: Sellers, I and E, and a consumer Period 1: Seller I and the buyer can make an exclusive contract. Period 2: Seller E decides.
Insights from economic- epidemiology Ramanan Laxminarayan Resources for the Future, Washington DC.
Market Failures Rebecca Tuttle Baldwin. Market Failure Market mechanism (price signal) fails to deliver what is socially optimum Justification for government.
Harcourt, Inc. items and derived items copyright © 2001 by Harcourt, Inc. Monopoly u A monopoly is the sole seller of its product.  its product does not.
Two Goals of Today’s Talk 1.Review some research on the value of increased longevity 2.Link the results of that research to important policy questions.
Access to HCV medicines and patent law Ellen ‘t Hoen, Medicines Law & Policy Seychelles September 2014.
Antitrust Policy and Regulation Chapter 18 McGraw-Hill/Irwin Copyright © 2009 by The McGraw-Hill Companies, Inc. All rights reserved.
How can Seychelles in future obtain affordable, good quality medicines for HIV/AIDS, Hepatitis C, cancer and other non-communicable diseases? Medical View.
Copyright © 2010, All rights reserved eStudy.us Market Structure – A classification system for the key traits of a market, including.
Explorations in Economics
Access to medicines, WTO TRIPS and Seychelles patent law Ellen ‘t Hoen, Medicines Law & Policy Seychelles September 2014.
Economic Policymaking Chapter 17. Economic Systems Market Economy: An economic system in which individuals and corporations, not the government, own the.
Monopoly. Monopoly A monopoly is one business firm that produces the entire market supply of a particular good or service. A monopoly is one business.
MARKET GOVERNMENT GOVERNMENT FAILURE INTERVENTION FAILURE EXTERNALITY PUBLIC ENTERPRISE ADMINISTRATIVE -PUBLIC GOODS-NATIONALIZATION COST MARKET -PRIVATIZATION.
1 Monopoly and Antitrust Policy Chapter IMPERFECT COMPETITION AND MARKET POWER imperfectly competitive industry An industry in which single firms.
Eco 6351 Economics for Managers Chapter 7. Monopoly Prof. Vera Adamchik.
MARKET GOVERNMENT GOVERNMENT FAILURE INTERVENTION FAILURE EXTERNALITY PUBLIC ENTERPRISE ADMINISTRATIVE -PUBLIC GOODS-NATIONALIZATION COST MARKET -PRIVATIZATION.
 How firms compete Easy as PIE: Presenting in English 09/03/2011.
Electronic Commerce and Economic Policy. Policy Issues Antitrust Policies –Promotion of competition –Regulation of uncompetitive markets Information Policies.
MICROECONOMICS: Theory & Applications
Biomedical Research Objective 2 Biomedical Research Methods.
MERGERS Clayton 7 as amended by the Celler-Kefauver Act:
Date: April 14, 2011 Topic: Regulation and Deregulation Aim: How does the government protect and promote competition? Do Now: Read the article. Read the.
Antitrust Policy and Regulation Chapter 18 McGraw-Hill/Irwin Copyright © 2009 by The McGraw-Hill Companies, Inc. All rights reserved.
 Economics  What’s Economics about? ♦ Science of making decisions to allocate scarce resources to alternative uses. ♦ Three fundamental questions: –
MFJ International, LLC A Global Consulting Firm “FTAs and Pharmaceuticals: a hijacked process?” M. Fabiana Jorge CPTECH November 16, 2006.
Chapter 12 Imperfectly Competitive Markets.  There are three categories of imperfect competition among sellers Monopoly Monopolistic Competition Oligopoly.
Economic Policymaking Chapter 17. Economic Systems Market Economy: An economic system in which individuals and corporations, not the government, own the.
1 Economic Analysis in Competition Law – A Lawyer’s Perspective A. Douglas Melamed March 23, 2009.
Should riskier drugs be approved for lethal diseases? Carolyn Johnson September 1, 2015 Washington Post
1.  exists when a single firm is the sole producer of a product for which there are no close substitutes. 2.
Chapter 7 section 3 The Role of Government.
The Case for a Free Market in Prescription Drugs Dean Baker, Co-director Center for Economic and Policy Research January 16, 2016.
More About Managed Care Markets. Plan for Today Market power Market evolution Last in-class team meeting –Final peer evaluation form –Your feedback on.
Balancing revenues and costs for orphan drugs: a case study Aidan Hollis University of Calgary: Department of Economics and O’Brien Institute of Public.
MICROECONOMICS: Theory & Applications By Edgar K. Browning & Mark A. Zupan John Wiley & Sons, Inc. 11 th Edition, Copyright 2012 PowerPoint prepared by.
Aim:What is market structure? HW:pg 154 # 1,5 9Hxy-TuX9fs.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024 Clinical Trial Management System.
Market Structures 4 Different Types.
CASE FAIR OSTER ECONOMICS P R I N C I P L E S O F
Monopoly 12-1.
MICROECONOMICS: Theory & Applications
Monopoly Structure and Conduct
“New Gene Therapy Treatments Will Carry Whopping Price Tags”
Public Policy to Promote Competition
Biomedical Research Examining types of biomedical research methods, their benefits and limitations.
Do Now Discuss with a partner…. “How many companies make cereal?”
Market Structure Wrap-Up
Government Intervention
Market Structure Wrap-Up
Market Structure Firm Behavior and the Role of Government
America’s $10 Billion Overspend on Sofosbuvir-Based Hepatitis C Treatment Resulting from Unmerited Patents Good afternoon. Pleased to be here to present.
“The Interest to Promote Competition Vs
Market Structures.
Public Policy to Promote Competition
Chapter 7: Market Structures Section 4
Economics Chapter 7.
Objective 2 Biomedical Research Methods
Regulatory Perspective of the Use of EHRs in RCTs
Presentation transcript:

Access and/or Protection? Andrey Shastitko MSU, RANEPA

No free lunch!!!

Sofosbuvir Brand name Sovaldi Against hepatitis C of all genotipes Higher efficiency (up to 97% vs. about 40% Peg- interferon+ribavirin) Weaker adverse effects High price (about 90 thousand Euro per cure per person) Cost of production – around100 times lower (depending on genotipes) Approximately 2% of the world population is infected Access for not more than 10% hard up persons

IPR and Monopoly IPR = exclusivity, not always monopoly (in antitrust sense) If IPR is monopoly - WHERE? Market for IPR? Product based on IPR used vs. IPR as a good? Product boundaries for market? Vertically differentiated product? Monopolistic pricing?

Compulsory Licensing? It is worth noting that a report issued earlier this year from the Global Commission on Drug Policy, which includes former Federal Reserve Chairman Paul Volcker and billionaire businessman Richard Branson, suggested that compulsory licenses should be pursued when pricing talks with drugmakers fail. Silverman, E. Will The New Hepatitis C Drugs Trigger A Battle Over Cost? / Forbes,

If it would be the last drug needed for last disease, probably, the answer would be much easier… But it is not the case.

Simple economics of Access and Protection Production costs are not the only costs which determine price of a drug, the clinical trials for FDA approval and R&D costs must also be taken into consideration (Vishwanathan M. I-MAK files pre-grant opposition against Gilead’s antiviral drug Sofosbuvir // grant-opposition-against-gileads-antiviral-drug-sofosbuvir.html). Economic organization: R&D – production-sales. Whether commerzialization is vertically integrated? Where is the good? What good is actually sold? What about incentives of different groups of players?

But nevertheless… Do we have biases in estimates of actual and potential beyond simple discounting?

What is the full price in Access- Protection trade-off? Externalities with drugs production (merit goods)? Material incentives is only thing to be considered of might be considered? Whether behavioral aspects does matter for discussion from “life or death” perspectives? Whether shared values have some meaning for this issues discussion? If yes, to what extent?

Thank you!